Social Capital Suvretta Holdings Corp. III (NASDAQ:DNAC) announced this morning that its shareholders approved its combination with drug developer ProKidney at a special meeting held yesterday afternoon.
An 8-K that was also filed this morning disclosed that 22,829,769 of DNAC ordinary shares were presented for redemption, representing 91.319% of DNAC’s trust. ProKidney received total gross proceeds of approximately $597 million from the transaction, which it expects to use to fund Phase 3 study of REACT, accelerate manufacturing scale-out, and prepare for its global commercial launch to treat patients with late-stage chronic kidney disease and at high risk of kidney failure.
The approval comes just one week after DNAC adjourned its original special meeting citing that the parties needed additional time to satisfy “conditions to closing of the Business Combination with respect to approval by The Nasdaq Capital Market of a listing application” for the combined company’s shares.
The newly formed company is named ProKidney Corp. and its shares will start trading on the Nasdaq under the symbol “PROK” today, July 12, 2022.
The parties initially announced their $1.8 billion combination on January 18. Winston-Salem, North Carolina-based ProKidney has launched Phase III trials of its REACT cellular therapy which promises to slow the progression of chronic kidney disease (CKD) and potentially regenerate tissues and function.
ADVISORS
- Citigroup acted as sole financial advisor and capital markets advisor to ProKidney.
- Citigroup, Morgan Stanley, Evercore, Jefferies, and UBS acted as placement agents for a portion of the PIPE.
- BofA Securities acted as capital markets advisor to SCS.
- Wachtell, Lipton, Rosen & Katz acted as legal advisor to SCS.
- Davis Polk & Wardwell LLP and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C acted as legal advisors to ProKidney.
- Winston & Strawn LLP is serving as legal advisor to the PIPE placement agents.
Terms Tracker for the Week Ending November 22, 2024 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. SPACs finally broke the DeSPAC announcement drought exactly 30 days from the last DeSPAC announcement with Hudson Acquisition I Corp.’s news they had reached the...
Hudson I (NASDAQ:HUDA) has signed a definitive agreement to combine with EV maker Aiways Europe at an equity value of $410 million. Munich, Germany-headquartered Aiways Europe is developing a line of EV SUVs for the European market with support from an affiliate manufacturer in China. The combined company is expected to trade on the Nasdaq...
The clearest theme for the changes to come under the incoming Trump administration is lower taxes domestically and trade barriers abroad. And, the election’s impacts on the investment climate have been broadly favorable to SPACs, but this policy-making direction could have detrimental impacts on SPAC deals themselves. That’s because international targets have made up an...
At the SPAC of Dawn Activity has been picking up in SPACland after a sleepy start to the month, but the biggest news for the this corner of the market is not SPAC-specific. SEC Chair Gary Gensler announced his intention to resign on January 20. His resignation press release touted the $21 billion in penalties...
Deals and Amendments Arogo Capital (OTC:AOGO) has received notice that its merger target Ayurcann Holdings (CSE:AYUR) has terminated their business combination citing a breach on behalf of the SPAC. Ayurcann expects to be paid a $250,000 breakup free from Arogo. News and Rumors PR: Smart TV firm Innovid (NYSE:CTV), which combined with ION 2 in...